Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone

Bone metastases are prevalent in many common cancers such as breast, prostate, and lung cancers, and novel therapies for treating bone metastases are needed. Human immune system-engrafted models are used in immuno-oncology (IO) studies for subcutaneous cancer cell or patient-derived xenograft implan...

Full description

Saved in:
Bibliographic Details
Main Authors: Tiina E. Kähkönen, Mari I. Suominen, Jenni H. E. Mäki-Jouppila, Jussi M. Halleen, Azusa Tanaka, Michael Seiler, Jenni Bernoulli
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2019/4260987
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568380016558080
author Tiina E. Kähkönen
Mari I. Suominen
Jenni H. E. Mäki-Jouppila
Jussi M. Halleen
Azusa Tanaka
Michael Seiler
Jenni Bernoulli
author_facet Tiina E. Kähkönen
Mari I. Suominen
Jenni H. E. Mäki-Jouppila
Jussi M. Halleen
Azusa Tanaka
Michael Seiler
Jenni Bernoulli
author_sort Tiina E. Kähkönen
collection DOAJ
description Bone metastases are prevalent in many common cancers such as breast, prostate, and lung cancers, and novel therapies for treating bone metastases are needed. Human immune system-engrafted models are used in immuno-oncology (IO) studies for subcutaneous cancer cell or patient-derived xenograft implantations that mimic primary tumor growth. Novel efficacy models for IO compounds on bone metastases need to be established. The study was performed using CIEA NOG (NOG) mice engrafted with human CD34+ hematopoietic stem cells (huNOG) and age-matched immunodeficient NOG mice. Bone phenotyping was performed to evaluate baseline differences. BT-474 human breast cancer cells were inoculated into the tibia bone marrow, and cancer-induced bone changes were monitored by X-ray imaging. Bone content and volume were analyzed by dual X-ray absorptiometry and microcomputed tomography. Tumor-infiltrating lymphocytes (TILs) and the expression of immune checkpoint markers were analyzed by immunohistochemistry. Bone phenotyping showed no differences in bone architecture or volume of the healthy bones in huNOG and NOG mice, but the bone marrow fat was absent in huNOG mice. Fibrotic areas were observed in the bone marrow of some huNOG mice. BT-474 tumors induced osteoblastic bone growth. Bone lesions appeared earlier and were larger, and bone mineral density was higher in huNOG mice. huNOG mice had a high number of human CD3-, CD4-, and CD8-positive T cells and CD20-positive B cells in immune-related organs. A low number of TILs and PD-1-positive cells and low PD-L1 expression were observed in the BT-474 tumors at the endpoint. This study reports characterization of the first breast cancer bone growth model in huNOG mice. BT-474 tumors represent a “cold” tumor with a low number of TILs. This model can be used for evaluating the efficacy of combination treatments of IO therapies with immune-stimulatory compounds or therapeutic approaches on bone metastatic breast cancer.
format Article
id doaj-art-a35f2d7de1be424eb06ef17d42763d76
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-a35f2d7de1be424eb06ef17d42763d762025-02-03T00:59:17ZengWileyJournal of Immunology Research2314-88612314-71562019-01-01201910.1155/2019/42609874260987Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal BoneTiina E. Kähkönen0Mari I. Suominen1Jenni H. E. Mäki-Jouppila2Jussi M. Halleen3Azusa Tanaka4Michael Seiler5Jenni Bernoulli6Pharmatest Services, Turku 20520, FinlandPharmatest Services, Turku 20520, FinlandPharmatest Services, Turku 20520, FinlandPharmatest Services, Turku 20520, FinlandTaconic Biosciences, Rensselaer, 12144 NY, USATaconic Biosciences, Rensselaer, 12144 NY, USAPharmatest Services, Turku 20520, FinlandBone metastases are prevalent in many common cancers such as breast, prostate, and lung cancers, and novel therapies for treating bone metastases are needed. Human immune system-engrafted models are used in immuno-oncology (IO) studies for subcutaneous cancer cell or patient-derived xenograft implantations that mimic primary tumor growth. Novel efficacy models for IO compounds on bone metastases need to be established. The study was performed using CIEA NOG (NOG) mice engrafted with human CD34+ hematopoietic stem cells (huNOG) and age-matched immunodeficient NOG mice. Bone phenotyping was performed to evaluate baseline differences. BT-474 human breast cancer cells were inoculated into the tibia bone marrow, and cancer-induced bone changes were monitored by X-ray imaging. Bone content and volume were analyzed by dual X-ray absorptiometry and microcomputed tomography. Tumor-infiltrating lymphocytes (TILs) and the expression of immune checkpoint markers were analyzed by immunohistochemistry. Bone phenotyping showed no differences in bone architecture or volume of the healthy bones in huNOG and NOG mice, but the bone marrow fat was absent in huNOG mice. Fibrotic areas were observed in the bone marrow of some huNOG mice. BT-474 tumors induced osteoblastic bone growth. Bone lesions appeared earlier and were larger, and bone mineral density was higher in huNOG mice. huNOG mice had a high number of human CD3-, CD4-, and CD8-positive T cells and CD20-positive B cells in immune-related organs. A low number of TILs and PD-1-positive cells and low PD-L1 expression were observed in the BT-474 tumors at the endpoint. This study reports characterization of the first breast cancer bone growth model in huNOG mice. BT-474 tumors represent a “cold” tumor with a low number of TILs. This model can be used for evaluating the efficacy of combination treatments of IO therapies with immune-stimulatory compounds or therapeutic approaches on bone metastatic breast cancer.http://dx.doi.org/10.1155/2019/4260987
spellingShingle Tiina E. Kähkönen
Mari I. Suominen
Jenni H. E. Mäki-Jouppila
Jussi M. Halleen
Azusa Tanaka
Michael Seiler
Jenni Bernoulli
Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
Journal of Immunology Research
title Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
title_full Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
title_fullStr Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
title_full_unstemmed Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
title_short Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone
title_sort human immune system increases breast cancer induced osteoblastic bone growth in a humanized mouse model without affecting normal bone
url http://dx.doi.org/10.1155/2019/4260987
work_keys_str_mv AT tiinaekahkonen humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT mariisuominen humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT jennihemakijouppila humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT jussimhalleen humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT azusatanaka humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT michaelseiler humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone
AT jennibernoulli humanimmunesystemincreasesbreastcancerinducedosteoblasticbonegrowthinahumanizedmousemodelwithoutaffectingnormalbone